, , 2017.
, Pharmacogenetics in cardiovascular diseases: State of the art and implementationrecommendations of the French National Network of, Pharmacogenetics
, Therapie, vol.72, issue.2, pp.257-67
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications, Lancet, vol.353, issue.9154, pp.717-726, 1999. ,
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose, N Engl J Med, vol.352, issue.22, pp.2285-93, 2005. ,
, , 2009.
, Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy, JAMA, vol.302, issue.8, pp.849-57
Genetic determinants of response to clopidogrel and cardiovascular events, N Engl J Med, vol.360, issue.4, pp.363-75, 2009. ,
DOI : 10.1056/nejmoa0808227
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement, Circulation, vol.121, issue.4, pp.512-520, 2010. ,
DOI : 10.1161/circulationaha.109.885194
URL : https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.109.885194
Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism, Pharmacol Res, vol.118, pp.33-42, 2017. ,
, PRADAXA® : Résumé des caractéristiques du produit, 2017.
, XARELTO® : Résumé des caractéristiques du produit, 2015.
, ELIQUIS® : Résumé des caractéristiques du produit, 2017.
, LIXIANA® : Summary of Product Characteristics
, Information/human/002629/WC500189045.pdf, consulté le 28 août, 2018.
Perioperatively acquired disorders of coagulation, Curr Opin Anaesthesiol, vol.28, issue.2, pp.113-135, 2015. ,
DOI : 10.1097/aco.0000000000000176
URL : http://europepmc.org/articles/pmc4418784?pdf=render
LIXIANA® : Avis de la commission de transparence du ,
, Rapport d'évaluation des médicaments anticoagulants oraux, 2018.
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Kardiol Pol, vol.74, issue.12, pp.1359-469, 2016. ,
News in the Indications of Direct Oral Anticoagulants According to the American College of Chest Physicians, Guidelines. Curr Drug Metab, vol.18, issue.7, pp.651-657, 2016. ,
Prise en charge des surdosages en antivitamines K, des situations à risque hémorragique et des accidents hémorragiques chez les patients traités par antivitamines K en ville et en milieu hospitalier, 2008. ,
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, vol.3, pp.692-696, 2005. ,
, , 2017.
, ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways, J Am Coll Cardiol, vol.70, issue.24, pp.3042-67
Measurement and reversal of the direct oral anticoagulants, Blood Rev, vol.31, issue.1, pp.77-84, 2017. ,
International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants, Thromb Haemost, vol.118, issue.3, pp.437-50, 2018. ,
Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor, J Thromb Thrombolysis, vol.32, issue.2, pp.183-190, 2011. ,
Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls, Thromb Haemost, vol.107, issue.2, pp.379-87, 2012. ,
, , 2017.
, Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP), Anaesth Crit Care Pain Med, vol.36, issue.1, pp.73-79, 2015.
Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatranassociated postcardiac surgery bleeding, Blood, vol.119, issue.9, pp.2172-2176, 2012. ,
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy), J Am Coll Cardiol, vol.63, issue.4, pp.321-329, 2014. ,
, , 2017.
, Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants: An Observational Registry Analysis, Anesthesiology, vol.127, issue.1, pp.111-131
Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication, J Thromb Thrombolysis, vol.41, issue.2, pp.241-248, 2016. ,
Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants, 2017. ,
Randomized Evaluation of Long Term Anticoagulant Therapy With Dabigatran Etexilate (RE-LY), 2018. ,
An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation (ROCKET-AF), vol.00403767, 2018. ,
, , 2013.
, Management of major bleeding complications and emergency surgery in patients on longterm treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP)-March, Arch Cardiovasc Dis, vol.106, issue.6-7, pp.382-93, 2013.
Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study, Eur Heart J, vol.38, issue.31, pp.2431-2440, 2017. ,
Early hemorrhage growth in patients with intracerebral hemorrhage, Stroke, vol.28, issue.1, pp.1-5, 1997. ,
Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran, J Pharm Pract, vol.28, issue.6, pp.548-54, 2015. ,
, , 2017.
, Idarucizumab for Dabigatran Reversal-Full Cohort Analysis, N Engl J Med, vol.377, issue.5, pp.431-472
, PRAXBIND® : Résumé des caractéristiques du produit, 2016.
A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran, Thromb Haemost, vol.113, issue.5, pp.943-51, 2015. ,
Reversing the anticoagulation effects of dabigatran, Hosp Pract, vol.45, issue.2, pp.29-38, 2017. ,
DOI : 10.1080/21548331.2017.1298389
URL : https://touroscholar.touro.edu/author_agreement.pdf
Reversal of Dabigatran Anticoagulant Effect With Idarucizumab (RE-VERSEAD), 2018. ,
Intravenous thrombolysis for stroke after Dabigatran reversal with Idarucizumab: an update, J Thromb Thrombolysis, vol.43, issue.4, pp.528-537, 2017. ,
DOI : 10.1007/s11239-017-1485-1
Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis, J Neurol, vol.264, issue.3, pp.591-595, 2017. ,
DOI : 10.1007/s00415-017-8410-6
FXa-?2Macroglobulin Complex Neutralizes Direct Oral Anticoagulants Targeting FXa In Vitro and In Vivo, Thromb Haemost, vol.118, issue.9, pp.1535-1544, 2018. ,
DOI : 10.1055/s-0038-1667014
URL : http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0038-1667014.pdf
Direct oral anticoagulant associated bleeding, J Mal Vasc, vol.41, issue.4, pp.272-280, 2016. ,
, , 2016.
, Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors, N Engl J Med, vol.375, issue.12, pp.1131-1172
, , 2018.
, Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors, Blood Adv, vol.2, issue.16, pp.2104-2118
Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study, Clin Pharmacokinet, vol.49, issue.4, pp.259-68, 2010. ,
Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development, Thromb Haemost, vol.103, issue.3, pp.572-85, 2010. ,
Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant, J Med Toxicol, vol.7, issue.4, pp.281-288, 2011. ,
, , 2014.
, Impact of endogenous esterase activity on in vitro p-glycoprotein profiling of dabigatran etexilate in Caco-2 monolayers, Drug Metab Dispos, vol.42, issue.2, pp.250-256
The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans, Drug Metab Dispos, vol.36, issue.2, pp.386-99, 2008. ,
The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban), Expert Opin Drug Metab Toxicol, vol.13, issue.7, pp.725-764, 2017. ,
Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism, Thromb J, vol.12, p.22, 2014. ,
The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans, Curr Drug Metab, vol.3, issue.6, pp.561-97, 2002. ,
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs, Pharmacogenomics J, vol.11, issue.4, pp.274-86, 2011. ,
Functional gene variants of CYP3A4, Clin Pharmacol Ther, vol.96, issue.3, pp.340-348, 2014. ,
CYP3A4-Cytochrome P450 3A4-Homo sapiens (Human)-CYP3A4 gene & protein, 2018. ,
CYP3A5-Cytochrome P450 3A5-Homo sapiens (Human)-CYP3A5 gene & protein, 2018. ,
Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control, Eur J Biochem, vol.218, issue.2, pp.585-95, 1993. ,
, NCBI. rs35599367 : Reference SNP Cluster Report, 2018.
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nat Genet, vol.27, issue.4, pp.383-91, 2001. ,
, Reference SNP Cluster Report ** With drug-response allele **, 2018.
, , 2004.
, Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population, Hum Mutat, vol.23, issue.1, p.100
Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs, J Biochem Mol Toxicol, vol.13, issue.6, pp.289-95, 1999. ,
The transcriptional regulation of the human CYP2C genes, Curr Drug Metab, vol.10, issue.6, pp.567-78, 2009. ,
Regulation of CYP2C19 expression by estrogen receptor ?: implications for estrogendependent inhibition of drug metabolism, Mol Pharmacol, vol.78, issue.5, pp.886-94, 2010. ,
CYP2C19-Cytochrome P450 2C19-Homo sapiens (Human)-CYP2C19 gene & protein, 2018. ,
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans, J Biol Chem, vol.269, issue.22, pp.15419-15441, 1994. ,
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19, Pharmacogenet Genomics, vol.22, issue.2, pp.159-65, 2012. ,
Characterization of the human MDR1 gene, AAPS J, vol.7, issue.1, pp.1-5, 2005. ,
Polymorphisms in the ABC drug transporter gene MDR1, Pharmacogenomics J, vol.1, issue.1, pp.59-64, 2001. ,
Regulation of volume-activated chloride channels by P-glycoprotein: phosphorylation has the final say, J Physiol, vol.524, issue.3, pp.629-665, 2000. ,
Structure of Pglycoprotein reveals a molecular basis for poly-specific drug binding, Science, vol.323, issue.5922, pp.1718-1740, 2009. ,
ABCB1-Multidrug resistance protein 1-Homo sapiens (Human)-ABCB1 gene & protein, 2018. ,
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein), Pharmacogenet Genomics, vol.21, issue.3, pp.152-61, 2011. ,
ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research, Pharmacogenomics J, vol.7, issue.3, pp.154-79, 2007. ,
DOI : 10.1038/sj.tpj.6500413
URL : https://www.nature.com/articles/6500413.pdf
, NCBI. rs1128503 : Reference SNP Cluster Report ** With Benign allele **, 2018.
, NCBI. rs2032582 : Reference SNP Cluster Report ** With drug-response, 2018.
, NCBI. rs1045642 : Reference SNP Cluster Report ** With drug-response allele **, 2018.
, NCBI. rs4148738 : Reference SNP Cluster Report, 2018.
, Identification of functionally variant MDR1 alleles among European Americans and African Americans, 2001.
, Clin Pharmacol Ther, vol.70, issue.2, pp.189-99
Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene, Pharmacogenetics, vol.13, issue.8, pp.481-94, 2003. ,
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability, Pharmacogenet Genomics, vol.15, issue.10, pp.693-704, 2005. ,
, , 2017.
, Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin, J Thromb Haemost, vol.15, issue.2, pp.273-83
Combined Influence of Genetic Polymorphism and DNA Methylation on ABCB1 Expression and Function in Healthy Chinese Males, Eur J Drug Metab Pharmacokinet, vol.42, issue.4, pp.627-634, 2016. ,
The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect, Drug Metabol Drug Interact, vol.29, issue.3, pp.143-51, 2014. ,
Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender, Biochem Pharmacol, vol.119, pp.76-84, 2016. ,
Genetic determinants of dabigatran plasma levels and their relation to bleeding, Circulation, vol.127, issue.13, pp.1404-1416, 2013. ,
CES1-Liver carboxylesterase 1 precursor-Homo sapiens (Human)-CES1 gene & protein, 2018. ,
The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty, Pharmgenomics Pers Med, vol.11, pp.127-164, 2018. ,
, , 2016.
, Pharmacogenetics of dabigatran etexilate interindividual variability, Thromb Res, vol.144, pp.1-5
Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect, Front Pharmacol, vol.7, p.494, 2016. ,
, , 2018.
, CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis, Genet Test Mol Biomarkers, vol.22, issue.1, pp.51-55
, , 2001.
, Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos, J Pharmacol Exp Ther, vol.299, issue.3, pp.825-856
, , 2016.
, ABCB1 SNP rs4148738 modulation of apixaban interindividual variability, Thromb Res, vol.145, pp.24-30
Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation, Pharmacogenet Genomics, vol.27, issue.9, pp.329-365, 2017. ,
Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke, Pharmgenomics Pers Med, vol.11, pp.43-52, 2018. ,
Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives, Per Med, vol.15, issue.3, pp.209-230, 2018. ,
An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure, Pharmacogenomics J, vol.18, issue.1, pp.153-162, 2018. ,
Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines, Sci Rep, vol.8, issue.1, p.10514, 2018. ,
Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels, Antimicrob Agents Chemother, vol.59, issue.4, pp.2305-2319, 2015. ,
, Transfusions de globules rouges homologues : produits, indications, alternatives, 2014.
Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections, Int J Antimicrob Agents, vol.47, issue.2, pp.124-155, 2016. ,
Impact of CYP3A4 Genotype on Voriconazole Exposure, Clin Pharmacol Ther, vol.103, issue.2, pp.185-191, 2018. ,
Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation, Br J Clin Pharmacol, vol.84, issue.6, pp.1301-1313, 2018. ,
Pharmacogenomics knowledge for personalized medicine, Clin Pharmacol Ther, vol.92, issue.4, pp.414-421, 2012. ,
Determination of rivaroxaban in patient's plasma samples by anti-Xa chromogenic test associated to High Performance Liquid Chromatography tandem Mass Spectrometry (HPLC-MS/MS), PLoS ONE, vol.12, issue.2, p.171272, 2017. ,
Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation, Thromb Res, vol.136, issue.1, pp.148-53, 2015. ,
Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban, Thromb Haemost, vol.110, issue.4, pp.723-754, 2013. ,
, Evaluation of glomerular filtration rate and proteinuria for the diagnosis of chronic kidney disease, Nephrol Ther, vol.5, issue.4, pp.302-307, 2009.
First reported case series in the United States of hemopericardium in patients on apixaban, HeartRhythm Case Rep, vol.4, issue.2, pp.82-86, 2017. ,
Atrial fibrillation: prevalence, risk factors and mortality in a large French population with 15 years of follow-up, Bull Acad Natl Med, vol.191, issue.4-5, pp.791-805, 2007. ,
, , 2015.
, Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists, Thromb Res, vol.136, issue.4, pp.749-53
Heavy menstrual bleeding on rivaroxaban, Br J Haematol, vol.173, issue.2, pp.314-319, 2016. ,
Heavy menstrual bleeding on Rivaroxaban-Comparison with Apixaban, Br J Haematol, vol.176, issue.5, pp.833-838, 2017. ,
Major bleeding with apixaban in atrial fibrillation: patient characteristics, management, and outcomes, Hosp Pract, pp.1-5, 1995. ,
Early Outcome after Intracranial Hemorrhage Related to Non-Vitamin K Oral Anticoagulants, Interv Neurol, vol.7, issue.1-2, pp.19-25, 2018. ,
Role of pharmacogenomics in the management of traditional and novel oral anticoagulants, Pharmacotherapy, issue.12, pp.1192-207, 2011. ,
Repeated bleeding complications during therapy with vitamin K antagonists in a patient with the VKORC1*2A and the CYP2C9*3/*3 alleles: genetic testing to support switching to new oral anticoagulants, Thromb Res, vol.131, issue.3, pp.279-80, 2013. ,
, , 2018.
, Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants, Oncotarget, vol.9, issue.49, pp.29238-58